Investors Expect Biopharma Run-Up To Cool In Summer, Heat Up In Fall
Executive Summary
Biotech and pharma stocks have continued their hot streak unabated this year, but if the summer brings little news and a broader market pull-back the sector is likely to cool. Wall Street is hopeful that any chill will be gone by the fall, with more clinical and regulatory milestones.
You may also be interested in...
Deals Of The Week Wonders: Who Will Buy Onyx?
Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back
Mortality for this deadly disease has been pushed back due to therapeutic innovations. But to make further strides, new mechanisms of action and combination approaches will need to come further into play. These advances and the eventual genericization of Velcade are likely to make the regulatory and payer environment increasingly complicated.